Full-Time
Clinical Trial Manager
Kymera Therapeutics
201-500 employees
Biotech company engineering targeted protein degraders
Compensation Overview
$115k - $200k/yr
Belmont, MA, USA
In Person
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to Kymera Therapeutics
See people who can refer or advise you
- Bachelor of Science in Life Sciences
- 3+ years (CTM) / 5+ years (Sr. CTM) as a project/clinical trial manager in biotech/pharmaceutical industry
- Experience working on large, global, complex Phase 2 clinical trial(s)
- Broad knowledge of regulatory and ICH GCP guidelines, HIPAA, Protection of Human Research Subjects
- Strong project management skills with the ability to manage multiple trials simultaneously
- Excellent problem-solving, leadership, and communication skills
- Ability to work in a fast-paced, dynamic environment with cross-functional teams
- Contribute to the planning, implementation and execution of a global clinical trial
- Responsible for management of vendors to support clinical trial execution
- Plan, execute, and lead study-specific meetings (e.g., internal core team meetings, investigator meetings, etc), as needed
- Provide input for the design of the Informed Consent Form(s), eCRFs, monitoring conventions, edit checks, etc.
- Provide study-specific training and leadership to clinical research staff, CRO, CRAs, sites and other contract personnel.
- Manage study timelines and metrics to ensure completion of study deliverables
- Support site selection, qualification, initiation, and monitoring activities.
- Review monitoring reports to ensure quality and resolution of site-related issues.
- Ensure timely enrollment and data collection at clinical trial sites.
- Collaborate with the data management team to ensure data integrity and timely database lock.
- Review and analyze clinical trial data to identify trends and potential issues.
- Ensure tracking and review of protocol deviations and assess impact on study data
- Develop relationships with investigators and site staff
- Work closely with CRO and Medical Monitor to ensure safety and efficacy data appropriately summarized to facilitate review.
- Work closely with translational medicine team to ensure appropriate incorporation of bioanalytical sampling plan into clinical protocols and relevant data output of the trial is provided to functional groups for review.
- Maintain accurate and complete trial documentation.
- Proactively identify and resolve clinical project issues
Kymera Therapeutics develops therapies that remove disease-causing proteins using targeted protein degradation. The company’s Pegasus Platform helps identify which proteins to degrade and then uses molecules that recruit the cell’s waste machinery to break down those proteins, aiming to treat cancers and immune diseases. This approach can create multiple drug candidates across different diseases. Kymera’s products are advanced through collaborations, most notably with Sanofi, which supports research, licensing, and milestone-based payments. Unlike traditional drugs that inhibit a protein’s function, Kymera’s strategy eliminates the protein itself, potentially offering new treatment options for patients. The company’s goal is to deliver new, effective medicines by degrading harmful proteins, expanding options in the biopharmaceutical market and addressing unmet medical needs.
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2016
Get referred to Kymera Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Kymera reported $65 million Q2 2026 collaboration revenue on August 5, 2026.
- Cash reached $1.5 billion on June 30, 2026, funding runway into 2029.
- Kymera finished KT-621 atopic dermatitis enrollment early, pulling Phase III start to mid-2027.
What critics are saying
- KT-621 Phase 2b can still fail after strong Phase 1b biomarker data.
- Kymera lost CMO Jared Gollob on July 27, 2026, while scaling late-stage trials.
- A bad KT-621 or KT-579 readout in 2026 can collapse Kymera’s TPD valuation story.
What makes Kymera Therapeutics unique
- Kymera built Pegasus for oral targeted protein degradation, not antibodies or biologics.
- KT-621 is first-in-class STAT6 degrader; KT-579 is first-in-class oral IRF5 degrader.
- Sanofi and Gilead validated Kymera’s platform with option exercises and milestones in 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↓ -2%Kymera Therapeutics has completed enrollment for its Phase 2b atopic dermatitis trial approximately six months ahead of schedule, driven by investigator enthusiasm for a once-daily oral therapy. Top-line data for the STAT6 degrader KT-621 is now expected by year-end 2026, with Phase III initiation pulled forward to mid-2027. The company reported $65 million in collaboration revenue during Q2 2026, including a $45 million option exercise fee from Gilead and a $20 million milestone from Sanofi. Cash runway extends into 2029, expected to fund Phase 2b completion and most Phase III development for the lead programme. Management is preparing infrastructure to execute over 10 Phase III studies across immunology over the next two to three years. The company appointed Terence Rooney as chief medical officer to lead late-stage development.
Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares on 7 July 2026 for approximately $6.0 million, according to an SEC filing. The transaction involved exercising fully vested stock options at a strike price of $2.08 per share and selling the resulting shares at a weighted average price of $119.00. The sale was executed under a Rule 10b5-1 trading plan adopted on 24 March 2026. Despite the transaction, Mainolfi retains 666,568 shares valued at $79.5 million, plus 90,000 stock options. The sale followed a 170% total return over the previous 12 months. Kymera Therapeutics, a clinical-stage biopharmaceutical company based in Watertown, focuses on developing protein degradation therapeutics for immunology and inflammation disorders.
Kymera Therapeutics has appointed Penny Carlson as Senior Vice President, Development Operations, to oversee global clinical development operations across its oral immunology portfolio. The clinical-stage biopharmaceutical company also announced that Chief Operating Officer Jeremy Chadwick will retire, remaining as an adviser through year-end. Carlson brings over 20 years of biopharmaceutical leadership experience in clinical programme management, study execution and data management. She joins from Takeda, where she served as Vice President and Head of Global Clinical Development Operations, leading clinical trial planning and execution across regions and therapeutic areas. Her appointment comes as Kymera advances multiple programmes through mid- and late-stage development. The company develops oral small molecule degrader medicines for immunological diseases.
Kymera Therapeutics appoints Penny Carlson as Senior Vice President, Development Operations. By GlobeNewswire June 9, 2026 Penny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Penny Carlson as Senior Vice President, Development Operations. Ms. Carlson brings more than two decades of biopharmaceutical leadership experience across clinical program management, study execution and data management, with a track record of advancing novel programs across multiple therapeutic areas. In her new role, she will oversee Kymera's global clinical development operations as the Company advances multiple programs through mid- and late-stage development. Kymera also announced that Jeremy Chadwick will retire from his role as Chief Operating Officer and will remain as an advisor to the Company through the end of the year. "We're thrilled to welcome Penny to our team at this important stage in our growth. Her proven leadership and deep expertise in shaping global development strategies across large immunology indications will be instrumental as we continue to advance our pipeline through clinical development and toward commercialization," said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. "I would like to sincerely thank Jeremy for his dedication and many contributions to Kymera's success throughout the company's remarkable growth." "I was drawn to Kymera by its unwavering commitment to rigorous and ambitious scientific innovation and meaningful clinical impact," said Ms. Carlson. "I am thrilled to be joining the company at such an exciting time of progress and opportunity, and I look forward to working with the talented team at Kymera to help advance these programs for patients and prepare the company for the next phase of growth and development." Prior to joining Kymera, Ms. Carlson served as Vice President and Head of Global Clinical Development Operations at Takeda, where she led a global organization responsible for the planning and execution of clinical trials across regions and therapeutic areas. During her tenure at Takeda, she held several senior leadership roles overseeing global clinical development operations and strategy. Earlier in her career, Ms. Carlson held leadership positions at Millennium Pharmaceuticals, Aileron Therapeutics, and other organizations across the pharmaceutical and biotechnology industry. She received a Bachelor of Science in Mathematics from Allegheny College. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. Investor Contact: powered by Justine Koenigsberg 857-285-5300 Media Contact: Matthew Henson 857-285-5300
Kymera Therapeutics appoints Penny Carlson as Senior Vice President, Development Operations. Penny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Penny Carlson as Senior Vice President, Development Operations. Ms. Carlson brings more than two decades of biopharmaceutical leadership experience across clinical program management, study execution and data management, with a track record of advancing novel programs across multiple therapeutic areas. In her new role, she will oversee Kymera's global clinical development operations as the Company advances multiple programs through mid- and late-stage development. Kymera also announced that Jeremy Chadwick will retire from his role as Chief Operating Officer and will remain as an advisor to the Company through the end of the year. "We're thrilled to welcome Penny to our team at this important stage in our growth. Her proven leadership and deep expertise in shaping global development strategies across large immunology indications will be instrumental as we continue to advance our pipeline through clinical development and toward commercialization," said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. "I would like to sincerely thank Jeremy for his dedication and many contributions to Kymera's success throughout the company's remarkable growth." "I was drawn to Kymera by its unwavering commitment to rigorous and ambitious scientific innovation and meaningful clinical impact," said Ms. Carlson. "I am thrilled to be joining the company at such an exciting time of progress and opportunity, and I look forward to working with the talented team at Kymera to help advance these programs for patients and prepare the company for the next phase of growth and development." Prior to joining Kymera, Ms. Carlson served as Vice President and Head of Global Clinical Development Operations at Takeda, where she led a global organization responsible for the planning and execution of clinical trials across regions and therapeutic areas. During her tenure at Takeda, she held several senior leadership roles overseeing global clinical development operations and strategy. Earlier in her career, Ms. Carlson held leadership positions at Millennium Pharmaceuticals, Aileron Therapeutics, and other organizations across the pharmaceutical and biotechnology industry. She received a Bachelor of Science in Mathematics from Allegheny College. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.